Share on StockTwits

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) have earned a consensus recommendation of “Hold” from the eleven ratings firms that are covering the stock, Analyst Ratings Network.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $8.10.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 1.29% on Friday, hitting $7.0901. 517,605 shares of the company’s stock traded hands. Achillion Pharmaceuticals has a 52 week low of $2.26 and a 52 week high of $8.61. The stock has a 50-day moving average of $7.26 and a 200-day moving average of $4.41. The company’s market cap is $686.3 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.77 earnings per share for the current fiscal year.

ACHN has been the subject of a number of recent research reports. Analysts at JMP Securities upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Friday. They now have a $13.00 price target on the stock. Separately, analysts at Wells Fargo & Co. raised their price target on shares of Achillion Pharmaceuticals to $8.00 in a research note on Monday, June 23rd. Finally, analysts at Maxim Group raised their price target on shares of Achillion Pharmaceuticals from $6.00 to $22.00 in a research note on Monday, June 16th. They now have a “buy” rating on the stock.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.